NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download.

• Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits)

• New Drug Channels Institute Study: U.S. Drug Distribution Industry Gaining from Anti-Obesity Drugs and Provider-Administered Biosimilars (press release)

We’re offering special discounted pricing if you order before October 23, 2023!

The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our 14th edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. No other report on the market today offers the depth, insight and analysis into these channels

This 2023-24 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models.

The notable new material in this 2023-24 edition includes:

• New data about commercial pricing and reimbursement for provider-administered biosimilars appears in Section 3.2.2. and Section 6.4.3.

• A new Section 6.2.2. reviews the evolving specialty pharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution.

• A new Section 6.3.2. analyzes the acquisitions of physician practices by corporate entities and private equity firms

• A new Section 6.5. addresses the Inflation Reduction Act of 2022. In Subsection 6.5.1., we summarize the key provisions of the law that relate to prescription drugs. In Subsection 6.5.2., we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business.

• We provide updated, expanded, and reorganized data about the following markets:
  • Pharmacy services administrative organizations (Section 2.2.4.)
  • Group purchasing organizations for small pharmacies (Section 2.2.5.)
  • Group purchasing organizations for physician practices (Section 3.3.2.)
• Material that addresses COVID-19 and its impact on the wholesale channel has been integrated into our analyses throughout the report. However, we have retained and updated Section 6.1.4., which examines the distribution of COVID-19 vaccines and therapeutics.

• There are 163 exhibits in this 2023-24 edition, compared with 150 in the 2022-23 edition.

If you would like to pay by corporate purchase order or check, please email Tamra Feldman. If you preordered the report, you should have already received an email with download instructions. Please contact us if you did not receive the email.

WHAT’S GOING ON

Twice a year, I research and write two comprehensive, fact-based, and nonpartisan reports on drug channel economics. In some small way, I try to make the world a better and smarter place.

Licenses for our DCI reports are regularly purchased by nearly every entity involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more. So, you can find out what your customers, partners, and competitors are reading.

The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the only resource of its kind available anywhere. It offers 163 proprietary charts, exhibits, and data tables.

FOUR FUN FACTS

• The 9 chapters are self-contained and do not need to be read in order. (Really!) There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities.

• We are offering the option to download an additional PowerPoint file with images of all 163 exhibits. This popular option helps you share the insights and data with others in your organization. (The exhibits appear in all license versions. The PowerPoint file option is available only with the purchase of a corporate license.)

• There are more than 660 endnotes, most of which have hyperlinks to original source materials. These source materials offer a handy way to build your knowledge base beyond what’s included in the full report.

• As usual, I have reluctantly stripped out the corny jokes and pop culture references.

If you have any questions (before or after reading the report), please email me.

Enjoy!